- Home
- ASO vs AKRO Comparison
ASO vs AKRO Comparison
Compare ASO & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASO
- AKRO
- Stock Information
- Founded
- ASO 1938
- AKRO 2017
- Country
- ASO United States
- AKRO United States
- Employees
- ASO N/A
- AKRO N/A
- Industry
- ASO Recreational Games/Products/Toys
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ASO Consumer Discretionary
- AKRO Health Care
- Exchange
- ASO Nasdaq
- AKRO Nasdaq
- Market Cap
- ASO 2.5B
- AKRO 2.8B
- IPO Year
- ASO 2020
- AKRO 2019
- Fundamental
- Price
- ASO $39.22
- AKRO $39.85
- Analyst Decision
- ASO Buy
- AKRO Strong Buy
- Analyst Count
- ASO 18
- AKRO 9
- Target Price
- ASO $58.00
- AKRO $76.29
- AVG Volume (30 Days)
- ASO 1.4M
- AKRO 1.1M
- Earning Date
- ASO 06-10-2025
- AKRO 05-16-2025
- Dividend Yield
- ASO 1.31%
- AKRO N/A
- EPS Growth
- ASO N/A
- AKRO N/A
- EPS
- ASO 5.73
- AKRO N/A
- Revenue
- ASO $5,933,450,000.00
- AKRO N/A
- Revenue This Year
- ASO $4.71
- AKRO N/A
- Revenue Next Year
- ASO $6.78
- AKRO N/A
- P/E Ratio
- ASO $6.91
- AKRO N/A
- Revenue Growth
- ASO N/A
- AKRO N/A
- 52 Week Low
- ASO $33.34
- AKRO $17.86
- 52 Week High
- ASO $64.62
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- ASO 48.62
- AKRO 44.56
- Support Level
- ASO $37.01
- AKRO $41.60
- Resistance Level
- ASO $40.37
- AKRO $46.47
- Average True Range (ATR)
- ASO 1.28
- AKRO 2.26
- MACD
- ASO 0.60
- AKRO 0.08
- Stochastic Oscillator
- ASO 73.98
- AKRO 21.84
About ASO Academy Sports and Outdoors Inc.
Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports & recreation, and footwear.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.